December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NImmune Biopharma

News headline image
NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026
From NImmune Biopharma
Via Business Wire
News headline image
Leading the Next Wave of Innovative IBD Therapeutics Targeting Immunometabolism: Josep Bassaganya-Riera Launches Clinical Program and Business Venture to Develop NIM-1324 for Ulcerative Colitis and Crohn’s disease
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company Symposium
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease
From NImmune Biopharma
Via Business Wire
News headline image
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline
From NImmune Biopharma
Via Business Wire
News headline image
Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease
From NImmune Biopharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.